PDL BioPharma Inc. (OTCMKTS:PDLI) Raises $150 million Through Offering of Unsecured Convertible Notes


PDL BioPharma Inc. (OTCMKTS:PDLI) recently attended the Piper Jaffray Healthcare Conference, held in New York, on November 29, 2016. The company was represented by its CEO, John P. McLaughlin, whose presentation was also webcast live, on PDLI’s website. It should be noted that this was the 28th time the annual conference was held.

The presentation was conducted soon after PDL closed an offering of its convertible senior unsecured note, after having raised a total of $150 million. The notes are due on December 1, 2021, while the underwriters have been granted an option to purchase $22.5 million worth of additional notes, under the over-allotment option. Moreover, the issued notes also carry an interest rate of 2.75% per year, which is due to be paid on a bi-annual basis, on the 1st of June and December every year.

The company had earlier announced that RBC Capital Markets was to act as the only book-running manager for the offering, Piper Jaffray was appointed as the lead manager and Roth Capital Partners was the co-manager. Under the terms of the offering, the notes are not redeemable prior to the date of maturity. The notes would be convertible at a share price of $3.81. The conversion rate of the said notes has been set at 262.2951 shares per $1,000 principal amount of the notes.

Net proceeds from the offering amounted to $145.8 million, of which $14.4 million was used by PDLI for a capped call transaction, with an affiliate of RBC Capital Markets. Added to this, another $121.5 million of the amount was used for repurchase of senior convertible notes, due 2018, worth $120 million, at 4% interest. It should be noted here that the aforementioned capped call transaction ensures that potential dilution of PDLI’s common stock is offset, which the company would have to make, upon conversion of the notes. Moreover, PDL also announced that should the underwriters exercise the over-allotment option, the additional proceeds would be used for an additional capped call transaction.

PDL BioPharma Inc. (OTCMKTS:PDLI) had a trade volume of 2.81 million and gained 1.82% in terms of its share value, during the December 9 trading session, to close at $2.24 per share.


For consideration of being featured on WallstreetPR, contact editor@Wallstreetpr.com

Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any content posted on our website is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. WallStreetPR strongly recommends you consult a licensed or registered professional before making any investment decision. Neither WallStreetPR.com nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WallStreetPR often gets compensated for advertisement services that are disclosed on our disclaimer located at WallStreetPR.com/Disclaimer.